Drug intelligence / Profile preview

ITB200

Development stage: Preclinical
Lead developer: ITB-Med

Overview

ITB200 is a preclinical-stage therapeutic candidate under development by ITB-Med. It is being evaluated for potential applications in organ transplantation and the treatment of immune-mediated or autoimmune diseases. As of 2024, ITB-Med has not publicly disclosed the specific molecular target, mechanism of action, or modality (e.g., small molecule or biologic) for this asset. The program aligns with the company's broader focus on developing therapies that induce specific immune tolerance to prevent graft rejection and treat chronic inflammatory conditions.

Beyond the preview

Go deeper on ITB200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITB200.

Explore the full profile